Literature DB >> 21079964

[Are sarcoma centers needed in Germany? Experience gained with the Bonner GIST register].

E Wardelmann1, S Merkelbach-Bruse, H U Schildhaus, R Büttner.   

Abstract

Due to their rarity and multiple subtypes, there is scant experience with sarcomas. Any effective targeted therapy depends on precise diagnosis of the tumor group using molecular markers and, increasingly, mutation testing. The necessary histopathological expertise and molecular diagnostic tools are usually only found at specialized centers. Using the Bonner GIST register as an example, the advantages of this kind of register from a diagnostic and therapeutic perspective will be discussed. Material submitted for gastrointestinal stromal tumors and other mesenchymal tumors, as well as the supervision of pathological referencing for national and international studies have made accurate diagnosis and appropriate therapy strategies ever more possible. The introduction of epidemiological as well as interdisciplinary sarcoma registers is a prerequisite for the improvement of sarcoma diagnostics and therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21079964     DOI: 10.1007/s00292-010-1398-7

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  12 in total

1.  Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  P G Casali; J-Y Blay
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

2.  Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal.

Authors:  L G Kindblom; H E Remotti; F Aldenborg; J M Meis-Kindblom
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

3.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

Authors:  S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

4.  c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant.

Authors:  Eva Wardelmann; Iris Neidt; Erhard Bierhoff; Nicola Speidel; Christoph Manegold; Hans-Peter Fischer; Ulrich Pfeifer; Torsten Pietsch
Journal:  Mod Pathol       Date:  2002-02       Impact factor: 7.842

5.  Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden.

Authors:  Bengt Nilsson; Per Bümming; Jeanne M Meis-Kindblom; Anders Odén; Aydin Dortok; Bengt Gustavsson; Katarzyna Sablinska; Lars-Gunnar Kindblom
Journal:  Cancer       Date:  2005-02-15       Impact factor: 6.860

6.  Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors.

Authors:  Sabine Merkelbach-Bruse; Wolfgang Dietmaier; Laszlo Füzesi; Andreas Gaumann; Florian Haller; Julia Kitz; Antje Krohn; Gunhild Mechtersheimer; Roland Penzel; Hans-Ulrich Schildhaus; Regine Schneider-Stock; Ronald Simon; Eva Wardelmann
Journal:  BMC Med Genet       Date:  2010-07-04       Impact factor: 2.103

7.  Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors.

Authors:  Eva Wardelmann; Inge Losen; Volkmar Hans; Iris Neidt; Nicola Speidel; Erhard Bierhoff; Thomas Heinicke; Torsten Pietsch; Reinhard Büttner; Sabine Merkelbach-Bruse
Journal:  Int J Cancer       Date:  2003-10-10       Impact factor: 7.396

8.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Authors:  Charles D Blanke; Cathryn Rankin; George D Demetri; Christopher W Ryan; Margaret von Mehren; Robert S Benjamin; A Kevin Raymond; Vivien H C Bramwell; Laurence H Baker; Robert G Maki; Michael Tanaka; J Randolph Hecht; Michael C Heinrich; Christopher D M Fletcher; John J Crowley; Ernest C Borden
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

9.  Inflammatory fibroid polyps harbour mutations in the platelet-derived growth factor receptor alpha (PDGFRA) gene.

Authors:  H-U Schildhaus; T Cavlar; E Binot; R Büttner; E Wardelmann; S Merkelbach-Bruse
Journal:  J Pathol       Date:  2008-10       Impact factor: 7.996

10.  Liposarcoma: outcome based on the Scandinavian Sarcoma Group register.

Authors:  Katarina Engström; Peter Bergh; Pelle Gustafson; Ragnar Hultborn; Helena Johansson; Rickard Löfvenberg; Olga Zaikova; Clement Trovik; Ola Wahlström; Henrik C F Bauer
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.